About 2 results found for searched term "JBJ-09-063" (0.115 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M21081 | JBJ-09-063 | EGFR/HER2 |
| JBJ-09-063 is an oral allogenic epidermal growth factor inhibitor currently in preclinical development for the study of non-small cell lung cancer (NSCLC) with epidermal growth factor L858R mutations. | ||
| M56420 | JBJ-09-063 | EGFR/HER2 |
| JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor with IC50s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
